2.46
-0.81%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biodexa Pharmaceticals
Its shares trade under the ticker BDRX. It has been listed since 7 December 2015. In the fiscal year to 31 December 2023, it reported revenue of $511,190 and a net loss of $9.5m. At that date it held total assets of $14.1m and shareholders' equity of $6.3m.
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Dec 2015
- Employees
- 27
- Website
- biodexapharma.com ↗
- Head office
- 1 CASPIAN POINT, CARDIFF, CF10 4DQ
- Incorporated in
- X0
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biodexa Pharmaceuticals Plc operates in the Health Care sector with a focus on clinical stage biopharmaceuticals.
- The company has collaboration agreements with Janssen and Melior to support its development pipeline.
- It offers advanced drug delivery platforms such as Q-Sphera, MidaSolve, and MidaCore for targeted therapeutics.
Weaknesses
- The company has only 27 employees, which limits its operational scale.
- Its lead product candidate, Tolimidone, is currently only in Phase II studies for Type 1 diabetes.
- The company is based in Cardiff, which may restrict access to broader US-based resources despite its US listing.
Opportunities
- The company is developing MTX110 for recurrent glioblastoma and other rare brain cancers, expanding its therapeutic reach.
- Tolimidone's Phase II studies for Type 1 diabetes present a significant opportunity for market entry.
- The rebranding from Midatech Pharma plc to Biodexa Pharmaceuticals Plc in March 2023 may enhance its market identity.
Threats
- The company's products are in early clinical stages, posing risks of development failure.
- Competition in the Health Care industry for treatments of familial adenomatous polyposis and bladder cancer is intense.
- Reliance on collaboration agreements with partners like Janssen and Melior creates dependency risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.